Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mesoblast Advances Stem-Cell Drugs As Catalysts Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.

You may also be interested in...



After CEO’s Abrupt Resignation, Teva Management Emphasizes Stability

A day after announcing the abrupt resignation of CEO Jeremy Levin, Teva’s management emphasized that the company’s current strategy would continue, including plans for dealing with ongoing pressures from Copaxone’s loss of exclusivity, and under-performance of the European generics businesses. Teva hoped to persuade rattled investors of its steady road to growth.

Cardio3 BioSciences’ Stem Cell Heart Therapy Phase III Trials Bolstered By New Funding

Belgian biotech Cardio3 BioSciences is in a leading position in the race to develop a stem cell-based therapy for severe heart failure.

Australian Stem Cell Company Mesoblast To Get AU$170 Million Private Placement As Clinical Trials Ramp Up

Mesoblast Ltd., which Teva holds a 20% stake in, aims to raise AU$170 million by issuing new shares to a select group of existing and new global institutional investors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel